Exhibit 99.1

RADIATION THERAPY SERVICES HOLDINGS, INC.

Radiation Therapy Services Holdings, Inc. Reports Fourth Quarter

and Fiscal Year 2010 Financial Results

2010 Highlights:

·                  Acquisitions of a Myrtle Beach, South Carolina-based radiation therapy facility and four physician practices, expanding into new market

·                  Issued $310.0 million of Senior Subordinated Notes in April 2010; completed exchange offer for Senior Subordinated Notes in January 2011

·                  Completed advanced technology upgrades in six key markets

·                  Selected by key academic medical centers to serve as Developer and Managing Partner of first Proton Beam Radiation Therapy Center in New York

·                  2011 Physician Fee Schedule results in stable to slightly favorable reimbursement environment

·                  Strengthened management team with appointments of new CFO and COO

FORT MYERS, FL, February 28, 2011 — Radiation Therapy Services Holdings, Inc. (“Radiation Therapy Services”), a leading operator of radiation therapy centers, today announced financial results for the fourth quarter and fiscal year ended December 31, 2010.

For the fourth quarter of 2010, total revenues were $137.5 million and the net loss was $102.3 million.  For fiscal year 2010, total revenues were $544.0 million and the net loss was $113.8 million. The quarterly and annual net losses were due primarily to goodwill impairment charges in certain financially distressed markets.

“We finished 2010 with many accomplishments despite continued challenging economic conditions,” said Dr. Daniel Dosoretz, President and Chief Executive Officer.  “As a

1

result of the completion of strategic advanced technology upgrades in several markets, we were able to improve our RVUs per treatment at our same practice freestanding centers by 1.7%, compared to 2009, despite a 2.5% reduction in RVU values heading into 2010.  We believe these strategic upgrades will enable us to better meet future patient demands and prepare for more advanced treatments, including adaptive radiotherapy.

“We are also very pleased with our 2010 Myrtle Beach acquisitions, as the performance of those physician practices continues to exceed our expectations.  Lastly, we are very excited to be selected as developer and managing partner in the first proton beam radiation therapy center located in New York, which includes a consortium of five of the largest cancer center programs in New York City.  Looking forward, we expect a year of continued improvement in 2011 as we remain focused on growing our business, further deploying leading-edge technologies to advance patient care and making improvements in our operating performance.”

Fourth Quarter Financial 2010 Results

Total revenues increased 7.2% to $137.5 million in the fourth quarter of 2010, compared to $128.3 million in the fourth quarter of 2009.  The increase in revenue was principally due to $9.1 million in revenue from the May 2010 acquisition of the Myrtle Beach, South Carolina physician practices.

For the fourth quarter 2010, the Company reported 1,868 total treatments per day at its freestanding radiation oncology centers, up 2.3% as compared to the same period in 2009.

Same practice therapy revenue declined by 3.7% during the fourth quarter of 2010 principally as a result of lower volumes from the challenging economic environment in certain markets, including Michigan, Arizona and Nevada, and having one less treatment day versus the same period of the prior year.  Total RVUs per day at freestanding centers increased 1.2% in the fourth quarter versus the same period of the prior year.

Pro forma adjusted EBITDA for the fourth quarter of 2010 declined to $28.9 million, or 20.8% of total pro forma revenues, from $30.3 million, or 23.6% of total pro forma revenues for the fourth quarter of 2009, primarily resulting from the decrease in same practice treatments.  A reconciliation of net loss attributable to Radiation Therapy Services Holdings, Inc. shareholder determined in accordance with generally accepted accounting principles to pro forma adjusted EBITDA and total revenues determined in accordance with generally accepted accounting principles to total pro forma revenues for the quarters ended December 31, 2010 and 2009 is included in the attached supplemental information.

Net loss for the fourth quarter of 2010 was $102.3 million as compared to a net loss of $3.6 million for the fourth quarter of 2009.  The increase in net loss was primarily due to a goodwill impairment charge of $93.7 million related to the Company’s California, Arizona, Nevada and Florida East Coast markets as a result of the challenging economic environment in these areas.

2

Fiscal Year Financial 2010 Results

Total revenues increased 3.7% to $544.0 million for 2010, compared to $524.5 million for 2009.  The increase in revenue was principally due to revenue from the May 2010 acquisition of the Myrtle Beach, South Carolina physician practices and recognition of additional reimbursement from CMS under the Physician Quality Reporting Initiative (“PQRI”) of $23.8 million and $6.2 million, respectively.

For 2010, the Company reported 1,886 total treatments per day at its freestanding radiation oncology centers, down 0.9% as compared to 2009.

Same practice therapy revenue declined by 3.6% during 2010 principally as a result of lower volumes from the challenging economic environment in certain markets, including Michigan, California, Arizona, Nevada and the East Coast of Florida, and having one less treatment day versus the same period of the prior year.  Total RVUs per day at freestanding centers increased 0.5% during 2010 versus 2009.

Pro forma adjusted EBITDA for 2010 increased to $115.7 million, or 20.5% of total pro forma revenues, from $113.4 million, or 21.6% of total pro forma revenues for 2009, principally as a result of the favorable impact associated with the acquisitions of the Myrtle Beach, South Carolina and Princeton, West Virginia physician practices and a $4.0 million improvement in our provision for bad debts, net of the effect of decreases in our same practice treatments.  As a percentage of total pro forma revenues, pro forma adjusted EBITDA declined principally due to the growth of ancillary practice revenues which have inherently lower margins as they do not entail significant capital investments and to a lesser extent decreases in same practice treatments.  A reconciliation of net loss attributable to Radiation Therapy Services Holdings, Inc. shareholder determined in accordance with generally accepted accounting principles to pro forma adjusted EBITDA and total revenues determined in accordance with generally accepted accounting principles to total pro forma revenues for the years ended December 31, 2010 and 2009 is included in the attached supplemental information.

Net loss for 2010 was $113.8 million as compared to a net loss of $7.7 million for 2009.  The increase in net loss in 2010 was primarily due to a goodwill impairment charge of $93.7 million recorded in the fourth quarter of 2010 related to the Company’s California, Arizona, Nevada and Florida East Coast markets as a result of the challenging economic environment in these areas and a loss on early extinguishment of debt of $10.9 million.

2011 Outlook

“We are encouraged by the finalization of the 2011 Physician Fee Schedule, which provides for approximately a 9% increase in RVUs based on the current mix of our radiation oncology services. However, we expect that a 7.9% decline in the conversion factor as a result of budget neutrality adjustments will partially offset this increase,

3

resulting in an estimated 1-2% overall favorable impact in 2011,” continued Dr. Dosoretz.

“Similar to other healthcare providers, we believe in many markets patients are continuing to postpone visits to their primary care physicians and other providers that can lead to the early diagnosis and treatment of cancer.  Despite these specific market conditions, we remain very focused on numerous organic and corporate development initiatives that will better position the Company for long-term sustainable growth and improved patient care.

“We are making substantial improvements to our information systems to increase efficiencies and reduce costs; this includes the completion of pilots of our electronic health record solution in our Southwest Florida radiation oncology markets.  Combined with other actions taken to reduce our cost structure, these initiatives are expected to help us to preserve our margins in the near-term and will provide us with additional leverage as the Company continues to grow.

“We continue to be excited about the growth prospects in the large and growing radiation therapy market.  We expect that our continuous focus on clinical, operating and corporate development improvements will fortify Radiation Therapy Services’ position as the indisputable industry leader in the radiation oncology field and position the Company for sustainable success over the foreseeable future,” concluded Dr. Dosoretz.

Recent Developments

In February 2011, Radiation Therapy appointed Joseph M. Garcia to the newly created role of Chief Operating Officer.  Mr. Garcia brings to Radiation Therapy more than 15 years of operational experience in the healthcare services sector.  With the addition of Mr. Garcia to COO, and the March 2010 appointment of Mr. Kerrin E. Gillespie as Chief Financial Officer, Radiation Therapy has significantly expanded the breadth and experience of its executive management team.

Conference Call

Management will host a conference call on Tuesday, March 1, 2011 at 11:00 a.m. EST to discuss financial results, business conditions and other developments. The dial-in numbers are (877) 407-4018 for domestic callers, and (201) 689-8471 for international callers.  In addition, a telephonic replay of the call will be available until March 15, 2011.  The replay dial-in numbers are (877) 870-5176 for domestic callers and (858) 384-5517 for international callers.  Please use the conference ID number 365789 to access the replay.

About Radiation Therapy Services

Radiation Therapy Services, which operates radiation treatment centers primarily under the name of 21st Century Oncology, is a provider of advanced radiation therapy services

4

to cancer patients.  The Company’s 95 treatment centers are clustered into 28 local markets in 16 states, including Alabama, Arizona, California, Delaware, Florida, Kentucky, Maryland, Massachusetts, Michigan, Nevada, New Jersey, New York, North Carolina, Rhode Island, South Carolina and West Virginia.  The Company is headquartered in Fort Myers, Florida.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended.  These statements are based on management’s current expectations or beliefs about the Company’s future plans, expectations and objectives, including, but not limited to, the Company’s expected financial results and estimates for 2011.  These forward-looking statements are not historical facts and are subject to risks and uncertainties that could cause the actual results to differ materially from those projected in these forward-looking statements including, but not limited to the Company’s actual financial results and those risk factors that may be described from time to time in the Company’s filings with the Securities and Exchange Commission.  Readers of this release are cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date stated, or if no date is stated, as of the date of this press release. The Company undertakes no obligation to publicly update or revise the forward-looking statements contained herein to reflect changed events or circumstances after the date of this release, unless required by law.

5

RADIATION THERAPY SERVICES HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

(unaudited)

RADIATION THERAPY SERVICES HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands)

(unaudited)

RADIATION THERAPY SERVICES HOLDINGS, INC.

Supplemental Financial Information (Unaudited)

Reconciliation of Pro-forma Adjusted EBITDA to Net Loss Attributable

to Radiation Therapy Services Holdings, Inc. Shareholder

(1) Pro-forma Adjusted EBITDA is defined as income (loss) before interest expense (net of interest income), income taxes, depreciation and amortization, impairment loss, loss on sale of assets of a radiation treatement center, early extinguishment of debt, management fees from our sponsor, non-cash expenses including costs relating to stock compensation, amortization of straight-line rent and amortization of capital expenditures relating to repairs and maintenance, sale-lease back adjustments, acquisition-related costs, other expenses including loss on sale of assets, severance payments related to terminiation of employee staff reductions, tail premiums on termed physicians, cost savings implemented in 2009, litigation settlements with physicians, costs relating to remediation work on the material weakness associated with the provision for income taxes, costs associated with the restructuring of certain physician groups’ compensation agreements and pro-forma full period effect of acquisition EBITDA.

(a) Pro-forma amounts related to adjustments to total revenues and Pro-forma Adjusted EBITDA to reflect the full period effect of our acquisitions completed during 2010, including the purchase of the South Carolina physician practices in May 2010 and the acquisitions of the Princeton, West Virginia radiation oncology practice in December 2010.  The adjustments reflect the impact to our total revenues and Pro-forma Adjusted EBITDA as if the acquisition had occurred at the beginning of the year as follows: Pro-forma revenues includes $5.3 million related to Princeton, West Virginia practice and $16.1 million related to the South Carolina practices. Pro-forma acquisition EBITDA includes $3.1 million related to Princeton, West Virginia practice and $5.5 million related to the South Carolina practices.

(b) Management fees are fees paid to our sponsor, Vestar Capital Partners.

(c) Non-cash expenses including costs relating to stock compensation, amortization of straight-line rent and amortization of capital expenditures relating to warranty arrangements amortized to repairs and maintenance.

(d) Sale-lease back adjustments relates to the adjustment of benefit derived from the classification of operating leases as finance obligations reflecting a reclassification of interest expense and depreciation and amortization expense as rent expense.

(e) Acquisition related costs associated with the adoption of ASC 805 Business Combinations requiring prior capitalized costs be expensed, including professional fees and due diligence costs relating to the acquisition of physician practices.

(f) Other expenses include loss on sale of assets, severance payments related to termination of employee staff reductions, tail premiums paid on terminated physicians.

(g) Cost savings related to the planned initiative of cost cutting plans implemented during the fourth quarter of 2009.

(h) Litigation settlement relates to costs associated with the termination of physicians during 2010 as a result of the cost savings plans implemented in the fourth quarter of 2009.

(i) Material weakness expenses related to the costs associated with the remediation work on the material weakness for the provision for income taxes.

(j) Physician contracting expenses are costs associated with the restructuring of certain physician groups’ compensation arrangements.

We believe the Pro-forma Adjusted EBITDA provides useful information about our financial performance to investors, lenders, financial analysts and rating agencies since these groups have historically used EBITDA-related measures in the healthcare industry, along with other measures, to estimate the value of a company, to make informed investment decisions, to evaluate a company’s leverage capacity and its ability to meet its debt service requirements.  Pro-forma Adjusted EBITDA eliminates the uneven effect of non-cash depreciation of tangibles assets and amortization of intangible assets, much of which results from acquisitions accounted for under the purchase method of accounting.  Pro-forma Adjusted EBITDA is also used by us to measure individual performance for incentive compensation purposes and as an analytical indicator for purposes of allocating resources to our operating business and assessing their performance, both internally and relative to our peers, as well as to evaluate the performance of our operating management teams, and for purposes in the calculation of debt covenants and related disclosures.

Pro-forma Adjusted EBITDA is not intended as a substitute for net income (loss) attributable to Radiation Therapy Services Holdings, Inc. shareholder, operating cash flows or other cash flow data determined in accordance with accounting principles generally accepted in the United States. Due to varying methods of calculation, Pro-forma Adjusted EBITDA as presented may not be comparable to similarly titled measures of other companies.

RADIATION THERAPY SERVICES HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

RADIATION THERAPY SERVICES HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

RADIATION THERAPY SERVICES HOLDINGS, INC.

KEY OPERATING STATISTICS

(unaudited)